Niagen Bioscience, Inc. (NAGE)
NASDAQ: NAGE · Real-Time Price · USD
5.11
+0.05 (0.99%)
At close: Mar 9, 2026, 4:00 PM EDT
5.18
+0.07 (1.36%)
After-hours: Mar 9, 2026, 4:15 PM EDT

Company Description

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products.

The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products.

In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name.

The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers.

The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025.

Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Niagen Bioscience, Inc.
Niagen Bioscience logo
Country United States
Founded 1999
Industry Biotechnology
Sector Healthcare
Employees 104
CEO Robert Fried

Contact Details

Address:
10900 Wilshire Blvd, Suite 600
Los Angeles, California 90024
United States
Phone 310 388 6706
Website niagenbioscience.com

Stock Details

Ticker Symbol NAGE
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000851773
CUSIP Number 171077407
ISIN Number US1710774076

Key Executives

Name Position
Robert N. Fried Chief Executive Officer and Director
Frank Louis Jaksch Jr. Co-Founder and Chairman
Ozan Pamir C.F.A. Chief Financial Officer and Principal Accounting Officer
Carlos Lopez Senior Vice President and General Counsel
James Lee Controller
Dr. Andrew Shao Ph.D. Senior Vice President of Global Regulatory and Scientific Affairs
Michiko Kelley Chief Marketing Officer
Chu Yan Managing Director of Asia Pacific
Kendall Knysch Head of Media Relations and Partnerships
Wesley Yu Vice President of Finance